Promise already turning into fact: management shows the thing it told investors was coming is now measurably arriving, a
The model's full reasoning — Q4 2023 call → NO我们根据提供的财报电话会议记录,判断管理层是否指出了之前告诉投资者预期的增长性发展,并展示了当前实际活动证明该发展正在按计划或更快实现,同时表示该发展仍处于早期阶段。 关键点: - 管理层提到了与AbbVie的合作,特别是真皮填充剂产品。在2023年6月,他们宣布达到了一个重要里程碑,触发了1000万美元的付款。在本次电话会议上,他们提到该产品“现在处于临床开发阶段”,并且AbbVie在财报电话会议上表示预期美学市场增长,填充剂市场在多个季度下滑后预计回升。但管理层没有明确说“我们之前告诉过你们这个增长会到来”,而是描述了当前进展。 - 关于乳房植入物,他们提到正在进行大型动物研究,并计划在2024年第四季度和2025年第一季度报告结果。这似乎是新进展,但之前是否告诉过投资者?在2023年1月他们宣布了第一次大型动物研究结果,所以这是后续研究。但管理层没有明确说“我们之前预期这个研究会在此时进行”。 - 关于gut-on-a-chip,他们决定暂停,这不是增长性发展。 - 关于ESG,不是增长性发展。 核心问题:管理层是否明确指出了一个之前设定的增长预期,并展示了当前实际活动证明该预期正在实现,同时表示仍处于早期? 在电话会议中,Yehiel Tal说:“Throughout 2023 we made significant progress with AbbVie to advance this candidate towards commercialization. In June of last year, we announced the achievement of an important milestone under this collaboration, which triggered a $10 million payment from AbbVie to CollPlant.” 然后说“The dermal filler product candidate, which is our top focus, is now in the clinical phase of development”。这暗示了进展,但并没有明确说“我们之前告诉过你们这个产品会在2023年进入临床”之类的。实际上,在之前的电话会议中,他们可能已经提到过预期。但本次电话会议中,他们没有明确引用之前的预期。 另外,关于乳房植入物,他们说“We have begun an additional large animal study with clinically relevant commercial size implants.” 并说“We look forward to reporting results from this animal studies in the fourth quarter of this year and the first quarter of 2025.” 这似乎是新研究,但之前是否预期过?在2023年1月他们宣布了第一次研究结果,所以这是后续。但管理层没有说“正如我们之前所说,我们计划进行这项研究”。 关键点:管理层是否明确指出了一个之前设定的增长预期?在电话会议中,他们提到了“as we said”之类的吗?没有。他们只是描述了当前进展。 此外,关于AbbVie合作,他们提到“In their full year and fourth quarter conference call, AbbVie stated that they expect meaningful growth in the aesthetics market and that importantly, a ramping up is now anticipated after multiple quarters of decline in the U.S. filler market.” 这是引用AbbVie的预期,而不是CollPlant自己的预期。CollPlant没有说“我们之前告诉过你们这个市场会回升”。 因此,没有明确的三部分模式:没有明确指回之前设定的预期,没有展示当前实际活动作为确认(虽然提到了临床阶段,但那是进展,不是确认之前预期),也没有说“仍处于早期”之类的。 实际上,关于乳房植入物,他们说“We cannot stress enough the improvement that a regenerative breast implant could provide”但那是宣传,不是确认。 所以,答案应为NO。 但让我们再仔细看:管理层是否在说“我们之前告诉过你们这个产品会进入临床”?没有。他们只是陈述事实。 因此,答案是否定的。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| MCD | McDonald's Corporation | Q2 2024 | 2024-07-29 | D |
| AES | The AES Corporation | Q1 2024 | 2024-05-03 | C+ |
| ASB | Associated Banc-Corp | Q1 2024 | 2024-04-25 | A |
| DUOT | Duos Technologies Group, Inc. | Q4 2023 | 2024-04-01 | F |
| HP | Helmerich & Payne, Inc. | Q1 2024 | 2024-01-30 | C |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| SITM | SiTime Corporation | Q2 2023 | 2023-08-02 | C+ |
| DKS | DICK'S Sporting Goods, Inc. | Q4 2022 | 2023-03-07 | B |
| XHR | Xenia Hotels & Resorts, Inc. | Q2 2022 | 2022-08-05 | A |
| BRKL | Brookline Bancorp, Inc. | Q2 2022 | 2022-07-30 | B+ |
| UPWK | Upwork Inc. | Q2 2022 | 2022-07-27 | C+ |
| KD | Kyndryl Holdings, Inc. | Q4 2021 | 2022-03-01 | C+ |
| EXP | Eagle Materials Inc. | Q3 2022 | 2022-01-27 | B |
| WES | Western Midstream Partners, LP | Q3 2018 | 2018-10-31 | D |
| MAS | Masco Corporation | Q3 2018 | 2018-10-30 | C |
| AU | AngloGold Ashanti's | Q2 2018 | 2018-08-20 | B |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| ATI | Allegheny Technologies Incorporated | Q1 2018 | 2018-04-24 | B |
| INST | Instructure's | Q4 2017 | 2018-02-12 | B+ |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
| GNTX | Gentex Corporation | Q3 2017 | 2017-10-20 | B |
| MXL | MaxLinear, Inc. | Q2 2017 | 2017-08-08 | C+ |
| BIIB | Biogen Inc. | Q2 2017 | 2017-07-25 | B |
| CNS | Cohen & Steers, Inc. | Q2 2017 | 2017-07-20 | B |
| PTC | PTC Inc. | Q3 2017 | 2017-07-19 | C+ |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| ICFI | ICF International, Inc. | Q1 2017 | 2017-05-06 | B+ |
| PPG | PPG Industries, Inc. | Q1 2017 | 2017-04-20 | C |
| MDLZ | Mondelez International, Inc. | Q4 2016 | 2017-02-07 | C |
| BP | BP p.l.c. | Q4 2016 | 2017-02-07 | B+ |
| NTCT | NetScout Systems, Inc. | Q2 2017 | 2016-10-27 | D |
| F | Ford Motor Company | Q3 2016 | 2016-10-27 | B+ |
| MAT | Mattel, Inc. | Q3 2016 | 2016-10-19 | C |
| NDSN | Nordson Corporation | Q3 2016 | 2016-08-23 | A |
| VRNS | Varonis Systems, Inc. | Q2 2016 | 2016-08-09 | B+ |
| NWSA | News Corporation | Q2 2016 | 2016-08-08 | C+ |
| CGNX | Cognex Corporation | Q2 2016 | 2016-08-01 | A |
| TRV | The Travelers Companies, Inc. | Q2 2016 | 2016-07-21 | C+ |
| LBTYK | Liberty Global's | Q1 2016 | 2016-05-10 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| ESE | ESCO Technologies Inc. | Q2 2016 | 2016-05-03 | A |
| DD | DuPont de Nemours, Inc. | Q1 2016 | 2016-04-26 | B+ |
| HD | The Home Depot, Inc. | Q4 2015 | 2016-02-23 | A |
| SAN | Banco Santander, S.A. | Q4 2015 | 2016-01-27 | B |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
ICFI · Q1 2017 → YESThe question is: Does management point to a growth-bearing development that they previously told investors to expect, and now it's arriving with current activity, but still early with most contributio...YES Management explicitly references the themes from their February 2017 full-year earnings call (only two months prior), noting that the January-February pickup they had highlighted there continued through March. They then point to concrete current-period activity: ICF Olson won over $75 million in new revenue since acquisition (neither firm could have won independently), added substantial new-account wins in Q1, and saw its qualified pipeline rise significantly above year-end 2016 levels. John Wasson confirms the new projects and retainers are now lining up, with strong Q1 wins and momentum from added staff. Sudhakar states they expect mid-single-digit growth this 2017 and sequential improvement, while reiterating confidence in the medium-term outlook. The language makes clear the ramp is still early—H2 comparisons and most of the contribution lie ahead—matching the three-part pattern for this growth-bearing development. No other item in the call satisfies all three criteria as cleanly.
HOLX · Q4 2017 → YESThe question is about whether management points to a growth-bearing development they previously told investors to expect, and now it's arriving with current activity, but still early. YES The transcript shows a clear three-part pattern for international growth. Management explicitly references its prior expectation: “while we thought that international would be a double-digit grower by 2018, we've actually delivered on that promise a year earlier than anticipated.” In the just-reported Q4, they confirm the development with concrete activity 17.5% international growth (excluding Cynosure and blood), the sixth consecutive quarter of double-digit growth for molecular internationally, and Panther shipments exceeding prior-year levels. They also state it is still early with most contribution ahead: “we've actually delivered on that promise a year earlier,” and they hope investors remember this 2017 success story as they evaluate Cynosure 2.
PTC · Q3 2017 → YESThe question is about whether management points to a growth-bearing development they previously told investors to expect, and now it's arriving with current activity, but still early. YES Management explicitly references its prior long-term growth ambition for IoT (30-40% bookings growth, consistent with the faster-growing IoT market) as part of its double-digit overall plan, which it had communicated as the target to achieve sustainable growth. In the current quarter, it confirms this is materializing with 40%+ of IoT bookings from customer expansions, six-figure deals growing sequentially and year-over-year, and specific closed expansions with leading food/beverage, aerospace/defense, and medical device companies, plus strong contribution from these. It further conveys the development remains early by noting customers are "generally still in the early days of their IoT journeys" with "adoption is gaining momentum" and "further stages" (e.g.